Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4640449 | 0.79 | RAB9A (0.58) | ALDH1A1LMNASMN1; SMN2MAPK1RAB9A | |
| SCHEMBL30829417 | 0.76 | L3MBTL1 (0.68) | NR1H4ALDH1A1ROCK2ROCK1LMNA | |
| SCHEMBL10949279 | 0.76 | ALDH1A1 (0.69) | NR1H4ALDH1A1LMNADRD2ACHE | |
| SCHEMBL4640486 | 0.75 | L3MBTL1 (0.55) | LMNASMN1; SMN2HPGDMAPK1TDP1 | |
| SCHEMBL2919972 | 0.74 | SMN1; SMN2 (0.82) | NR1H4ALDH1A1LMNADRD2ACHE | |
| SCHEMBL5345421 | 0.74 | MMP13 (0.63) | NR1H4ROCK2ROCK1LMNASMN1; SMN2 | |
| SCHEMBL9543614 | 0.73 | MEN1 (0.67) | ALDH1A1LMNADRD2ACHESLC6A2 | |
| SCHEMBL4640433 | 0.72 | FYN (0.41) | ALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL30474381 | 0.72 | APEX1 (0.55) | ALDH1A1ROCK2ROCK1LMNACYP2C19 | |
| SCHEMBL29200010 | 0.72 | APEX1 (0.55) | ALDH1A1ROCK2ROCK1LMNACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6297283-B1 | EXCELLENT INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY AND ARE HENCE USEFUL AS ANTIALLERGIC AGENTS | KOWA CO., LTD. (JP) | 2001-10-02 | — | — | US | claimed |
| EP-0934924-B1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6576642-B2 | Inhibitors of the production of Ig E antibodies, antiallergens | KOWA CO., LTD. (JP) | 2003-06-10 | — | — | US | disclosed |
| US-20010039279-A1 | Diamide compounds and compositions containing the same | KOWA CO., LTD. (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6297283-B1 | EXCELLENT INHIBITORY EFFECT ON THE PRODUCTION OF AN IGE ANTIBODY AND ARE HENCE USEFUL AS ANTIALLERGIC AGENTS | KOWA CO., LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| EP-0934924-A1 | NOVEL DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039279-A1 | Diamide compounds and compositions containing the same | HRH4, HRH2, HRH1 | NR1H4 82/4885ALDH1A1 1240/4885ROCK2 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.